within Pharmacolibrary.Drugs.ATC.L;

model L01EJ04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.49,
    Cl             = 0.29333333333333333,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.0682,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008166666666666666,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Momelotinib is an orally bioavailable, small molecule inhibitor of Janus kinase 1 and 2 (JAK1/2) and activin A receptor type I (ACVR1). It is primarily used for the treatment of myelofibrosis, a type of myeloproliferative neoplasm, and is approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with myelofibrosis following oral administration.</p><h4>References</h4><ol><li><p>Xin, Y, et al., &amp; Silverman, JA (2018). Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment. <i>Journal of clinical pharmacology</i> 58(4) 522–532. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1050&quot;>10.1002/jcph.1050</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29283448/&quot;>https://pubmed.ncbi.nlm.nih.gov/29283448</a></p></li><li><p>Zheng, J, et al., &amp; Silverman, JA (2018). Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 46(3) 237–247. DOI:<a href=&quot;https://doi.org/10.1124/dmd.117.078899&quot;>10.1124/dmd.117.078899</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29311136/&quot;>https://pubmed.ncbi.nlm.nih.gov/29311136</a></p></li><li><p>Padda, SK, et al., &amp; Wakelee, HA (2022). A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. <i>Cancer chemotherapy and pharmacology</i> 89(1) 105–115. DOI:<a href=&quot;https://doi.org/10.1007/s00280-021-04369-0&quot;>10.1007/s00280-021-04369-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34773474/&quot;>https://pubmed.ncbi.nlm.nih.gov/34773474</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EJ04;
